The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.

@article{Rollier2015TheCG,
  title={The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.},
  author={Christine S Rollier and Christina Dold and Leanne Marsay and Manish Sadarangani and Andrew J Pollard},
  journal={Expert opinion on biological therapy},
  year={2015},
  volume={15 1},
  pages={131-42}
}
INTRODUCTION Capsular group B meningococcal disease is a leading cause of childhood meningitis and septicaemia. Up to 10% of sufferers die, and sequelae remain in > 30% of survivors. A vaccine, four component meningococcal group B ( 4CMenB ), designed with the aim to induce broad coverage against this highly variable bacterium, has been licensed in countries including in the European Union, Canada and Australia. AREAS COVERED Immunogenicity and safety data, published in peer-reviewed… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Similar Papers

Loading similar papers…